Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers

Maturitas

Volumn 60, Issue 2, 2008, Pages 71-77

  Biglia, N ^a   Mariani, L ^a   Ponzone, R ^a   Sismondi, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

BRCA; Breast cancer; Hormone replacement therapy; Oral contraceptives; Ovarian cancer; Salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; EDITORIAL; ENDOMETRIUM CANCER; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; OVARIECTOMY; OVARY CANCER; RISK REDUCTION; SALPINGOOOPHORECTOMY; TREATMENT DURATION;

BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS; OVARIECTOMY;

EID: 45849090747     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.03.004     Document Type: Editorial

References (38)

1. Ford D., Easton D.F., Bishop D.T., et al. Risks of cancer in BRCA1-mutation carriers. Lancet 343 (1994) 692-695
2. Antoniou A., Pharoah P.D.P., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (2003) 1117-1130
3. Easton D.F., Ford D., and Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers breast cancer linkage consortium. Am J Hum Genet 56 (1995) 265-271
4. Nourizinia M., Coupier I., and Pujol P. Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?. Cancer 104 (2005) 1567-1574
5. Ness R.B., Grisso J.A., Klapper J., et al. Oral contraceptives, other methods of contraception, and reduced risk for ovarian cancer. Epidemiology 12 (2001) 307-312
6. Bosetti C., Negri E., Trichopoulos D., et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 102 (2002) 262-265
7. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23.257 women with ovarian cancer and 87.303 controls. Lancet 371 (2008) 303-314
8. Narod S.A., et al., Hereditary Ovarian Cancer Clinical Study Group. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339 (1998) 424-428
9. Whittemore A.S., Balise R.R., Pharoah P.D.P., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91 (2004) 1911-1915
10. McGuire V., Felberg A., Mills M., et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160 (2004) 613-618
11. Modan B., Hartge P., Hirsh-Yechezel G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345 (2001) 235-245
12. McLaughlin J.R., Risch H.A., Lubinski J., et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8 (2007) 26-34
13. Kelsey J.L., Gammon M.D., and John E.M. Reproductive factors and breast cancer. Epidemiol Rev 15 (1993) 36-47
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer form 54 epidemiological studies. Lancet 346 (1996) 1713-1727
15. Milne R.L., Knight J.A., John E.M., et al. Oral contraceptive use and risk of early onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14 (2005) 350-356
16. Narod S.A., Dubé M.P., Klijn J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 (2002) 1773-1779
17. Haile R.W., Thomas D.C., McGuire V., et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15 (2006) 1863-1870
18. Brohet R.M., Goldgar D.E., Easton D.F., et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25 (2007) 3831-3836
19. Anderson K., Jacobson J.S., Heitjan D.F., et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144 (2006) 397-406
20. Bermejo-Pérez M.J., Márquez-Calderón S., and Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121 (2007) 225-231
21. Kauff N.D., and Barakat R.R. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 25 (2007) 2921-2927
22. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22 (2004) 2328-2335
23. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
24. King M.C., Marks J.H., Mandell J.B., and New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
25. Anglian Breast Cancer Study Group. Prevalence of penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83 (2000) 1301-1308
26. Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8 (2002) 3776-3781
27. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 20 23 (2005) 7491-7496
28. Levine D.A., Argenta P.A., Yee C.J., et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21 (2003) 4222-4227
29. Alvarado-Cabrero I., Young R.H., Vamvakas E.C., et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 72 (1999) 367-379
30. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
31. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
32. Beiner M.E., Finch A., Rosen B., et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations A prospective study. Gynecol Oncol 104 (2007) 7-10
33. Lavie O., Ben-Arie A., Pilip A., et al. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma-case report. Gynecol Oncol 99 (2005) 486-488
34. Nelson H.D., Vesco K.K., Haney E., et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295 (2006) 2057-2071
35. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A., et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15 (1997) 969-973
36. Madalinska J.B., van Beurden M., Bleiker E.M., et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24 (2006) 3576-3582
37. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23 (2005) 7804-7810
38. Armstrong K., Schwartz J.S., Randall T., et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22 (2004) 1045-1054